VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA/BLADDR 2020 | Second-line treatment of mHSPC

Ursula Vogl • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, explores the difficulties of sequencing second-line therapies for metastatic hormone-sensitive prostate cancer (mHSPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Vogl

1:41
Challenges and treatment advances in mHSPC
Ursula Vogl • 14 Oct 2020
1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020

Related Videos

3:37
Challenges of MRI in prostate cancer
Anwar Padhani • 14 Oct 2020
4:34
Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
Arlene Siefker-Radtke • 14 Oct 2020
1:41
Challenges and treatment advances in mHSPC
Ursula Vogl • 14 Oct 2020
1:25
Improving precision of high-quality prostate cancer MRI
Anwar Padhani • 14 Oct 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals